Home > Result Summaries: Compounds > ropinirole > Result Summary for 101468/043

Result Summary for 101468/043

Result Summary

Protocol ID:	101468/043
Clinical Study ID:	SKF-101468/043
Official Title:	A Double-Blind, Bromocriptine Controlled, Multicenter Study of Ropinirole at a Flexible Oral Dose of 0.25–8.0mg Three Times Daily for Six Months in the Treatment of Parkinsonian Patients Not Optimally Controlled on L-Dopa
Phase:	Phase 3
Study Indications or Diseases:	Parkinson Disease
Generic Name:	ropinirole
Trade/Product Name:	requip;requip
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Brunt ER, Brooks DJ, Korczyn AD et al. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson’s disease not optimally controlled by L-dopa. J Neural Transm 2002; 109: 489–502